Last reviewed 2026-04-20 · How we verify

Aethoheptazin (ETHOHEPTAZINE)

Phase 2 active Small molecule

Aethoheptazin (generic name: ETHOHEPTAZINE) is a drug. It is currently in Phase 2 development.

Aethoheptazine is thought to work by interacting with the central nervous system to produce a therapeutic effect.

Aethoheptazine, also known as ETHOHEPTAZINE, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known whether it is FDA approved or off-patent. The approved indications for Aethoheptazine are also unknown. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. Further research is needed to fully understand its mechanism of action and safety profile.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETHOHEPTAZINE
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is like a computer, and Aethoheptazine is like a software update that helps fix problems with how your brain is working. It does this by interacting with tiny molecules called receptors in the brain, which helps to regulate how your brain processes information and responds to stimuli.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Aethoheptazin CI brief — competitive landscape report
Aethoheptazin updates RSS · CI watch RSS

Frequently asked questions about Aethoheptazin

What is Aethoheptazin?

Aethoheptazin (ETHOHEPTAZINE) is a Small molecule drug.

How does Aethoheptazin work?

Aethoheptazine is thought to work by interacting with the central nervous system to produce a therapeutic effect.

What is the generic name of Aethoheptazin?

ETHOHEPTAZINE is the generic (nonproprietary) name of Aethoheptazin.

What development phase is Aethoheptazin in?

Aethoheptazin is in Phase 2.

Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing